Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults

2023141 citationsJournal Articlebronze Open Access

Authors

Ann R. Falsey · University of Rochester

Kristi L. Williams · Janssen (Netherlands)

Efi Gymnopoulou · Janssen (Belgium)

Stephan Bart

John Ervin

Arangassery Rosemary Bastian · Janssen (Netherlands)

Joris Menten · Janssen (Belgium)

Els De Paepe ·

Abstract

In adults 65 years of age or older, Ad26.RSV.preF-RSV preF protein vaccine was immunogenic and prevented RSV-mediated lower respiratory tract disease. (Funded by Janssen Vaccines and Prevention; CYPRESS ClinicalTrials.gov number, NCT03982199.).

Topics & Keywords

Respiratory viral infections research Animal Virus Infections Studies Viral Infections and Immunology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 388, Issue 7, pp. 609-620

DOI: 10.1056/nejmoa2207566

Field-Weighted Citation Impact: 30.34